Hyaluronic Acid Risks Patients Rarely Hear
New research documents hyaluronic acid risks from granulomas to autoimmune reactions. Here's what peer-reviewed studies say before your next filler appointment.
Key Takeaways
- A 2025 scoping review in the Brazilian Dental Journal found that vascular occlusion, granulomas, and hypersensitivity reactions are among the most clinically significant adverse events tied to hyaluronic acid facial injections.
- A Cureus case report documented Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) triggered by both hyaluronic acid filler and hyaluronidase — the enzyme commonly used to dissolve it.
- A Journal of Cranio-Maxillo-Facial Surgery study found that patients who received sequential injections of multiple filler materials developed refractory granulomas that required imaging-guided surgery to remove.
- A scoping review in the Journal of Clinical and Aesthetic Dermatology found that hyperbaric oxygen therapy shows promise for filler-induced vascular occlusion but lacks standardized protocols, leaving treatment highly variable.
- A JADA case report described lip filler granulomas that mimicked oral pathology, delaying correct diagnosis for months — a pattern that points to the need for cross-specialty awareness among dentists and injectors.
How common are serious hyaluronic acid risks in clinical studies?
Disclaimer: While hyaluronic acid carries certain risks that are important to understand, this section presents general educational information only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before undergoing any cosmetic procedure.
Serious hyaluronic acid risks are rare in clinical studies, but the complications that do occur can be severe, permanent, or even life-threatening. A 2025 scoping review cataloging adverse reactions and complications caused by hyaluronic acid injections in the face found that vascular occlusion — where filler blocks blood flow to tissue — stands as the most feared complication, capable of causing skin necrosis, blindness, or stroke when filler enters or compresses a blood vessel near the eye or brain.
The clinical literature shows this pattern:
Vascular occlusion frequency: The scoping review confirms vascular occlusion is uncommon but not vanishingly rare, and outcomes depend almost entirely on how fast the injector recognizes the problem and dissolves the filler with hyaluronidase. Minutes matter. A separate scoping review on hyperbaric oxygen therapy for filler-induced vascular occlusion found that delayed treatment dramatically worsens tissue outcomes, which means an injector who doesn’t stock hyaluronidase on-site is a red flag.
Granuloma formation: Delayed inflammatory nodules — granulomas — can appear months or years after injection. A case report documented lip filler granulomatous inflammation so severe it mimicked oral pathology and required biopsy to diagnose. A separate imaging-based surgical study found that patients who received sequential injections of multiple filler materials faced the most refractory granulomas, often requiring surgical removal.
Autoimmune reactions: A 2025 case analysis documented Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) triggered by both hyaluronic acid filler and hyaluronidase — the very antidote used to dissolve it. This is rare, but it means the rescue drug carries its own risk profile.
Under-eye injections carry specific danger: A comparative study on under-eye rejuvenation noted that the tear trough is a high-risk zone for vascular events and visible lumping, with complication rates higher than in other facial zones.
A 2025 review of injectable fillers and complications puts the overall serious-complication rate in context: most patients experience only minor swelling or bruising, but the subset who suffer vascular or inflammatory complications can face disfigurement requiring months of medical management. Low probability does not mean low consequence.
What is ASIA syndrome and can hyaluronic acid trigger it?
Disclaimer: This section presents general health information for consumer education only. It is not medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare professional before undergoing any cosmetic procedure.
ASIA syndrome — Autoimmune/Inflammatory Syndrome Induced by Adjuvants — is a recognized clinical condition. Hyaluronic acid can trigger it. The risks are real, documented in peer-reviewed literature, and serious enough that every consumer considering filler injections deserves a plain-language explanation of the mechanism.
Clinicians first described the syndrome in relation to silicone and vaccine adjuvants, but a 2025 case report documents ASIA triggered specifically by hyaluronic acid filler and by hyaluronidase — the enzyme injectors use to dissolve it. That second detail matters. The very rescue agent marketed as a safety net can itself provoke a systemic immune response in susceptible individuals.
ASIA symptoms can include chronic fatigue and muscle pain appearing weeks to months after injection, cognitive difficulties sometimes called “brain fog,” arthralgia and joint inflammation, skin rashes or sicca symptoms (dry eyes, dry mouth), and in severe cases, features overlapping with lupus, Sjögren’s syndrome, or other autoimmune conditions.
The 2025 ASIA case report is explicit: both the filler and the hyaluronidase used to reverse it acted as immune triggers in the same patient. Clinicians diagnosed the condition only after ruling out other autoimmune diseases — a process that took time and specialist involvement.
ASIA is not common. Millions of hyaluronic acid filler procedures are performed annually, and systemic autoimmune responses remain rare. A scoping review of filler adverse reactions categorizes most complications as local — vascular occlusion, granuloma formation, infection — rather than systemic. Rarity does not mean zero risk, and it does not mean a med spa’s front desk staff is equipped to recognize ASIA when it develops weeks after a patient has left the building.
Ask your provider directly whether they can distinguish a delayed hypersensitivity reaction from an early autoimmune response, and ask what their protocol is for patients who develop systemic symptoms after treatment. A provider who cannot answer that question clearly — or who dismisses the question — is not the right provider for you.
Why do multi-material filler injections raise the granuloma risk?
Disclaimer: This section contains general health and safety information for consumer education only. It is not medical advice, diagnosis, or treatment guidance. Consult a qualified, licensed healthcare professional before undergoing any cosmetic procedure.
Multi-material filler injections raise granuloma risk because layering different substances in the same tissue creates compounding foreign-body reactions that single-product treatments rarely trigger. Each additional material introduces a new antigen the immune system must evaluate—and when it cannot clear the substance, it walls it off in a granuloma, a dense cluster of inflammatory cells that can persist for years.
A 2025 case series published in a craniofacial imaging journal examined patients who developed refractory soft-tissue granulomas after receiving sequential injections of multiple filler types across separate sessions. Researchers found that the combination of materials—not any single product—drove the most treatment-resistant cases, with surgical excision ultimately required because standard pharmacologic management failed (PMID 42551060). Refractory means the granulomas did not respond to corticosteroids or other first-line treatments. That’s serious.
The mechanism works like this: hyaluronic acid fillers, calcium hydroxylapatite, poly-L-lactic acid, and permanent silicone each degrade—or don’t degrade—on different timelines and through different biological pathways. When a provider injects a second material into tissue that still contains a first, the immune system encounters a mixed-material depot it has no clean protocol for resolving. A scoping review of hyaluronic acid facial injection complications confirmed that delayed hypersensitivity reactions, including granuloma formation, represent one of the most clinically significant adverse event categories, and that prior filler history in the same anatomical zone is a recognized risk factor (PMID 42525051).
Before any filler appointment, ask your provider two specific questions:
- What filler material is currently in my tissue from prior treatments, and how does that affect today’s product choice?
- Have you reviewed imaging or prior treatment records before selecting injection depth and product type?
A provider who cannot answer the first question—or who dismisses it—is operating without the clinical picture the procedure requires. Research on injectable fillers and collagen stimulators documents that product selection must account for existing tissue composition, because placing a biostimulatory agent like poly-L-lactic acid into a zone already carrying hyaluronic acid changes the inflammatory environment in ways that increase complication risk (PMID 42479576). Granulomas from multi-material combinations can also be harder to image accurately, which delays diagnosis and complicates surgical planning when removal becomes necessary (PMID 42551060).
What happens when filler blocks a blood vessel and how is it treated?
Disclaimer: This section contains general health information only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before undergoing any cosmetic procedure.
When filler blocks a blood vessel, the consequences can escalate from skin discoloration to permanent tissue death within hours. Vascular occlusion happens when filler is injected into or compresses an artery, cutting off blood supply to surrounding tissue; a scoping review on HA complications identifies it as one of the most serious adverse events associated with facial filler injections.
The warning signs are specific and time-sensitive: blanching (sudden white or pale skin) at or near the injection site, a bluish-purple discoloration called livedo reticularis that signals compromised circulation, pain disproportionate to the procedure, or vision changes or sudden vision loss, which point to possible ophthalmic artery involvement.
Speed determines outcome. Research on injectable fillers and their complications confirms that hyaluronidase — an enzyme that dissolves hyaluronic acid filler — is the primary emergency intervention, and it must be administered as quickly as possible after occlusion is recognized. The provider injects hyaluronidase directly into the affected area in high doses to break down the filler and restore blood flow. Minutes matter. A provider who hesitates, misreads the signs, or lacks hyaluronidase on-site has already narrowed the treatment window.
Hyaluronidase is not a guaranteed fix. A scoping review on hyperbaric oxygen therapy documents cases where vascular occlusion caused lasting skin necrosis despite treatment, and found that hyperbaric oxygen therapy — breathing pure oxygen in a pressurized chamber — has been used as an adjunct to support tissue recovery after occlusion events, though the evidence base for it remains limited and the review calls for standardized protocols.
One critical point: hyaluronidase only dissolves hyaluronic acid fillers. Permanent or semi-permanent fillers — including calcium hydroxylapatite and poly-L-lactic acid — cannot be dissolved the same way, which makes vascular occlusion with those products significantly harder to reverse. The injectable fillers complications review notes this distinction directly.
Before booking any filler appointment, ask the provider two questions: Do you keep hyaluronidase on-site? And what is your written protocol if a vascular event occurs during treatment? A provider who cannot answer both questions clearly is not prepared for the complication that can end a patient’s vision or leave permanent facial scarring.
How do hyaluronic acid fillers compare to polynucleotides for safety under the eyes?
Disclaimer: This section presents general educational information only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified, licensed healthcare provider before pursuing any injectable procedure.
Hyaluronic acid (HA) fillers carry a broader, better-documented complication profile under the eyes than polynucleotides do—though polynucleotides are not risk-free, and long-term safety data on them remains sparse. The tear trough is one of the most unforgiving areas on the face for any injectable. Skill and credentials matter more than product choice.
What the evidence says about HA fillers under the eyes
A 2025 head-to-head review in Aesthetic Surgery Journal found that HA fillers produced higher rates of the Tyndall effect—a bluish discoloration from light scattering through superficially placed filler—along with edema and vascular complications in the periorbital region, per PMID 42452433. Polynucleotides showed a more favorable short-term safety profile, with fewer acute adverse events, though the authors flagged the limited volume of comparative trial data.
The broader HA complication picture is sobering. A scoping review catalogued adverse reactions from facial HA injections: vascular occlusion, skin necrosis, infection, and granuloma formation—PMID 42525051. Vascular occlusion ranks as the most urgent risk. The infraorbital and angular arteries run close to common tear trough injection points, and a misplaced bolus can compromise blood flow to the eye itself. A separate scoping review on hyperbaric oxygen therapy as rescue treatment for filler-induced vascular occlusion confirms these events occur and that treatment windows are narrow—PMID 42459244.
HA fillers carry one meaningful safety advantage: hyaluronidase can dissolve them. Polynucleotides have no reversal agent. If a polynucleotide injection goes wrong—wrong plane, wrong patient, wrong product—the provider cannot erase it.
Rare but serious systemic reactions have been documented with HA. A case series described Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) triggered by both hyaluronic acid and hyaluronidase itself—PMID 42483137. Granulomatous reactions, sometimes appearing months or years after injection, add another layer of long-term risk to HA products—PMID 42551060.
What consumers should ask before booking
- Is the provider licensed to inject in your state, and does their license specifically authorize this procedure?
- Can they demonstrate training in vascular anatomy of the periorbital region?
- Do they stock hyaluronidase on-site for emergency reversal of HA complications?
- For polynucleotides: is the product FDA-cleared or being used off-label, and has the provider disclosed that?
No product is categorically safe under the eyes. Provider training, anatomical knowledge, and emergency preparedness separate acceptable risk from preventable harm.
What should patients ask a provider before any filler appointment?
Before any filler appointment, patients should ask their provider direct questions about hyaluronic acid risks, credentials, complication protocols, and the specific products being injected. Skipping that conversation is how patients end up in emergency rooms — or worse, with permanent disfigurement.
Start with credentials. Ask the provider’s exact license type and whether they are authorized under your state’s scope-of-practice rules to inject fillers independently. A medical aesthetician and a board-certified physician are not interchangeable, and state licensing boards publish those records publicly. Walk out if a med spa deflects that question.
Then ask about complications — specifically these:
- Vascular occlusion. Filler injected into or near a blood vessel can cut off circulation to skin or, in rare cases, cause blindness. Ask whether the provider stocks hyaluronidase on-site and can administer it immediately. A scoping review on vascular occlusion management found that delayed treatment worsens outcomes; minutes matter.
- Granuloma formation. Delayed inflammatory nodules can appear months or years after injection, and they are notoriously difficult to treat. One case series on multi-material filler granulomas documented patients who required surgical excision after sequential injections from different providers. Ask whether the provider knows your full filler history before touching a needle.
- Autoimmune reactions. A published case report describes autoimmune/inflammatory syndrome triggered by both hyaluronic acid filler and hyaluronidase — the very antidote. Patients with autoimmune conditions should disclose them and ask how the provider would manage a systemic reaction.
- Lip-specific risks. Lip filler can produce granulomatous inflammation that mimics oral pathology, delaying correct diagnosis. A documented case shows how easily this gets misattributed to dental or mucosal disease.
Ask what product is being used by brand name and concentration. Hyaluronic acid fillers vary significantly in cross-linking density, longevity, and complication profile, and a comprehensive review of injectable fillers confirms that product selection should match the anatomical target — not the provider’s supply shelf.
Ask whether the provider has a written emergency protocol and a relationship with a nearby emergency facility. Ask how many vascular occlusion events they have personally managed. A provider who has never seen a complication may simply be inexperienced enough that one hasn’t happened yet.
One question most patients never think to ask: has anyone else injected filler into this area before, and does it matter? Research on adverse reactions from hyaluronic acid injections identifies prior filler as a risk factor for complications. Your provider needs that history.
This content is general health information for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed, qualified healthcare professional before undergoing any cosmetic procedure.
FAQ
What are the most serious hyaluronic acid risks documented in peer-reviewed research?
A 2025 scoping review in the Brazilian Dental Journal (PMID 42525051) identified vascular occlusion, granulomatous inflammation, and hypersensitivity reactions as the most clinically significant hyaluronic acid risks. Vascular occlusion is the most urgent because it can cause tissue death or, in rare cases, blindness if filler enters an artery near the eye.
Can hyaluronic acid filler cause an autoimmune reaction?
Yes. A 2025 Cureus case report (PMID 42483137) documented a patient who developed Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) after receiving hyaluronic acid filler and then hyaluronidase. Symptoms included systemic inflammation that persisted well after the injections.
Does mixing different filler brands or materials increase complication risk?
A study in the Journal of Cranio-Maxillo-Facial Surgery (PMID 42551060) found that patients who had received sequential injections of multiple filler types developed refractory granulomas that did not respond to standard medical treatment and required imaging-guided surgery. The authors concluded that mixing materials complicates both diagnosis and removal.
What is a filler granuloma and how is it diagnosed?
A granuloma is a localized inflammatory mass the body forms around a foreign substance it cannot break down. A JADA case report (PMID 42524773) described lip filler granulomas that looked like oral lesions, leading to months of misdiagnosis before the filler was identified as the cause.
Is hyperbaric oxygen therapy an effective treatment for filler vascular occlusion?
A 2025 scoping review in the Journal of Clinical and Aesthetic Dermatology (PMID 42459244) found case-level evidence that hyperbaric oxygen therapy can help salvage tissue after filler-induced vascular occlusion, but no standardized protocol exists. Treatment timing, pressure, and session number varied widely across the cases reviewed.
Are polynucleotide injections safer than hyaluronic acid fillers under the eyes?
A 2025 study in the Journal of Clinical Medicine (PMID 42452433) compared the two for under-eye rejuvenation and found polynucleotides produced fewer inflammatory side effects in that area, though both carried risks. The authors noted that the tear trough is a high-risk zone for any injectable because the skin is thin and vascular anatomy is variable.
What questions should I ask before getting a hyaluronic acid filler injection?
Ask the provider what filler material they plan to use, whether they have hyaluronidase on hand for emergencies, and what their protocol is if vascular occlusion occurs. A 2025 review in the Journal of Craniofacial Surgery (PMID 42479576) lists vascular anatomy knowledge and emergency reversal preparedness as minimum competency standards for anyone performing facial filler injections.
Can hyaluronidase itself cause a reaction?
Yes. The same Cureus case report (PMID 42483137) that documented ASIA syndrome noted that the patient’s reaction appeared to involve both the original hyaluronic acid filler and the hyaluronidase used to dissolve it. Providers and patients should be aware that the reversal agent is not risk-free.
This article is for general information and is not medical or legal advice. Med-spa regulations, licensing, and scope-of-practice rules vary by state — verify a provider’s credentials with your state medical or nursing board and consult a licensed professional before any treatment.